Newfeed

– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy –  – If approved, PADCEV with KEYTRUDA would be the first combination in Japan to offer an alternative to chemotherapy,

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: